Ana Paula Rodrigues
A5040282505- Influenza Virus Research Studies
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- COVID-19 epidemiological studies
- Pneumonia and Respiratory Infections
- Health Promotion and Cardiovascular Prevention
- Global Public Health Policies and Epidemiology
- Blood Pressure and Hypertension Studies
- Climate Change and Health Impacts
- Nutritional Studies and Diet
- Chronic Disease Management Strategies
- COVID-19 and healthcare impacts
- Bacterial Infections and Vaccines
- Data-Driven Disease Surveillance
- Employment and Welfare Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- SARS-CoV-2 detection and testing
- Health disparities and outcomes
- Diabetes and associated disorders
- Healthcare Regulation
- Maternal and Neonatal Healthcare
- Public Health in Brazil
- Health, Nursing, Elderly Care
National Institute of Health Dr. Ricardo Jorge
2015-2024
Administração Regional de Saúde de Lisboa e Vale do Tejo
2012-2024
Universidade Federal do Acre
2024
University of Minho
2021-2024
Ipca Laboratories (India)
2024
Universidade Federal do Pará
2024
Instituto Nacional de Saúde
2017-2024
Universidade de São Paulo
2024
New York University
2024
Hospital Sírio-Libanês
2023
A remarkable excess mortality has coincided with the COVID-19 pandemic in Europe. We present preliminary pooled estimates of all-cause for 24 European countries/federal states participating monitoring public health action (EuroMOMO) network, period March–April 2020. Excess particularly affected ≥ 65 year olds (91% all deaths), but also 45–64 (8%) and 15–44 (1%). No was observed 0–14 olds.
We describe the epidemiological characteristics, pattern of circulation, and geographical distribution influenza B viruses its lineages using data from Global Influenza Study. included over 1.8 million cases occurred in thirty-one countries during 2000–2018. calculated proportion caused by lineages; determined timing A epidemics; compared age B/Victoria B/Yamagata cases; evaluated frequency lineage-level mismatch for trivalent vaccine. The median virus was 23.4%, with a tendency (borderline...
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 vaccine effectiveness (IVE) estimates two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against than A(H3N2): EU-PC 53% (95% CI: 41 63) 30% −3 54) A(H3N2). For EU-H, these were 44% 30 55) 14% −32 43), respectively.
Weekly monitoring of European all-cause excess mortality, the EuroMOMO network, observed high mortality during influenza B/Yamagata dominated 2017/18 winter season, especially among elderly. We describe and influenza-attributable season in Europe.Based on weekly reporting from 24 countries or sub-national regions, representing 60% population excluding Russian Turkish parts Europe, we estimated age stratified morality using model. In addition, was FluMOMO algorithm, incorporating activity...
Since December 2016, excess all-cause mortality was observed in many European countries, especially among people aged ≥ 65 years. We estimated and influenza-attributable 19 countries/regions. Excess primarily explained by circulation of influenza virus A(H3N2). Cold weather snaps contributed some countries. The pattern similar to the last major A(H3N2) season 2014/15 Europe, although starting earlier line with early start.
Influenza disease burden varies by age and this has important public health implications. We compared the proportional distribution of different influenza virus types within strata using surveillance data from twenty-nine countries during 1999-2014 (N=358,796 cases). For each virus, we calculated a Relative Illness Ratio (defined as ratio percentage cases in an group to country population same group) for young children (0-4 years), older (5-17 adults (18-39 (40-64 elderly (65+ years). used...
Respiratory syncytial virus (RSV) infections are one of the leading causes lower respiratory tract and have a major burden on society. For prevention control to be deployed effectively, an improved understanding seasonality RSV is necessary.The main objective this study was contribute better by examining GERi multi-country surveillance dataset.RSV seasons were included in analysis if they contained ≥100 cases. Seasonality determined using "average annual percentage" method. Analyses...
The European monitoring of excess mortality for public health action (EuroMOMO) network monitors weekly all-cause in 27 countries or subnational areas. During the first wave coronavirus disease (COVID-19) pandemic Europe spring 2020, several experienced extraordinarily high levels mortality. is currently seeing another upsurge COVID-19 cases, and EuroMOMO again witnessing a substantial attributable to COVID-19.
Abstract Background Respiratory syncytial virus (RSV) is one of the leading causes acute respiratory tract infections. To optimize control strategies, a better understanding global epidemiology RSV critical. this end, we initiated Global Epidemiology in Hospitalized and Community care study (GERi). Methods Focal points from 44 countries were approached to join GERi share detailed surveillance data. Countries completed questionnaire on characteristics their system. Results Fifteen provided...
Through deterministic data linkage of health registries, mRNA vaccine effectiveness (VE) against COVID-19-related hospitalisations and deaths was measured in 1,880,351 older adults. VE 94% (95% confidence interval (CI): 88-97) 82% CI: 72-89) for those 65-79 ≥ 80 years old, with no evidence waning 98 days after dose two. mortality 96% 92-98) 81% 74-87) these two age groups.
Abstract Background Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season Europe, followed by higher circulation of A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated vaccine effectiveness (VE) using a multicentre test‐negative study. Materials Methods Primary practitioners collected information specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, (sub)type clade, age group, target group time since...
Introduction Determining the optimal time to vaccinate is important for influenza vaccination programmes. Here, we assessed temporal characteristics of epidemics in Northern and Southern hemispheres tropics, discuss their implications Methods This was a retrospective analysis surveillance data between 2000 2014 from Global Influenza B Study database. The seasonal peak defined as week with most reported cases (overall, A, B) season. duration activity using maximum proportion during three...
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. included 592 cases and 4,372 controls the main analysis. The VE was 62% (95% CI: 45–74) for one dose only 89% 79–94) complete vaccination. vaccines provide good protection presentation level, particularly fully vaccinated individuals.
Abstract Background In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure vaccine effectiveness (VE). Methods Primary practitioners collected information on patients presenting with acute respiratory infection. Cases were A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls virus negative. We calculated VE using logistic regression, adjusting for site, age, sex, onset date, presence of chronic...
In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. a multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September and January 2024. Using test-negative case–control design, VE in the target group for overall by time since vaccination. We included 1057 cases 4397 controls. Vaccine was 40 % (95 CI: 26–53 %) overall, 48 31–61 among those vaccinated < 6...
Background Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim We aimed to estimate primary series (PS) and first booster VE symptomatic BA.1/BA.2 infection investigate potential biases. Methods This test-negative multicentre study tested care patients with acute respiratory symptoms for the BA.1/BA.2-dominant period. estimated PS among adults adolescents (PS only) all products combined Comirnaty alone,...
In Health Examination Surveys interview information is complemented with objective information, providing more accurate indicators than self-reported data. We report the study design, planning and implementation of first Portuguese Survey (INSEF).INSEF was a cross-sectional population-based representative at regional national level. Individuals aged between 25 74 years old, residing in Portugal were selected from health users' registry through multi-stage stratified probabilistic sampling....
Introduction: The aim of this study was to estimate and describe the prevalence severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies (immunoglobulin M and/or immunoglobulin G) in Portugal May-July 2020.Material Methods: A cross-sectional seroepidemiological survey developed after peak first epidemic wave on a sample 2301 Portuguese residents, aged 1 year or older. Survey selected using two-stage stratified non-probability sampling design (quota sampling)....
Since the end of November 2023, European Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate 95.3 (95% CI: 91.7–98.9) all-cause deaths per 100,000 person-years for all ages. This is seen adults aged 45 years and older, coincides with widespread presence COVID-19, influenza respiratory syncytial virus (RSV) many countries during 2023/24 winter season.